期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 33, 期 1, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2020.101140
关键词
Multiple myeloma; Maintenance therapy; Neoplasms; Second primary; Minimal residual disease; Lenalidomide; Adaptive clinical trials
类别
资金
- Haematology Society of Australia and New Zealand New Investigator Scholarship
- Royal College of Pathologists of Australasia Mike and Carole Ralston Travelling Fellowship Award
With ten years of follow-up since the advent of the modern paradigm of combination induction therapy, consolidative autologous stem-cell transplant, and lenalidomide maintenance, median survival for multiple myeloma has increased to almost 50% at 10 years. Given this outlook, the overarching goal of maintenance therapy is to spare patients from the toxicities of aggressive or otherwise intrusive therapies while ideally extending survival or, at the least, extending progression-free survival or time until next treatment. This review will focus on the current landscape of maintenance therapies for multiple myeloma. The historical context and evidence for choice of agent, duration of treatment, and current strategies and ongoing trials will be discussed - as well as a focus on unmet needs. The case for studies investigating cessation of therapy and risk and response-adapted approaches will be underscored given that the current paradigm likely results in overtreatment for some patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据